Effect of an electronic health record on the culture of an outpatient medical oncology practice in a four-hospital integrated health care system: 5-Year experience

Journal of Oncology Practice

Volumn 7, Issue 4, 2011, Pages

  Brockstein, Bruce ^a,b   Hensing, Thomas ^a,b   Carro, George W ^a,b   Obel, Jennifer ^a,b   Khandekar, Janardan ^a,b   Kaminer, Lynne ^a,b   Van Wege, Christine De ^a,b   De Marsh, Robert Wilton ^a,b  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; BEVACIZUMAB; CETUXIMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

ARTICLE; BREAST CANCER; CHEMOTHERAPY; ELECTRONIC MEDICAL RECORD; HEALTH CARE QUALITY; HOSPITAL PATIENT; HUMAN; HYPERTENSION; INTEGRATED HEALTH CARE SYSTEM; MEDICAL PRACTICE; ONCOLOGY; OUTPATIENT CARE; PATIENT SAFETY; TOTAL QUALITY MANAGEMENT; UNITED STATES;

EID: 81855221184     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2011.000260     Document Type: Article

References (12)

1. Harshberger CA, Brockstein B, Carro G, et al.: Evaluation of outcomes before and after electronic medical record (EMR) and computerized physician order entry (CPOE) system implementation in an outpatient oncology setting. ASCO Meeting Abstracts 25:17058, 2007
2. Blumenthal D, Tavenner M: The "meaningful use" regulation for electronic health records. N Engl J Med 363:501-504, 2010
3. Robicsek A, Beaumont JL, Wright MO, et al.: Electronic prediction rules for methicillin-resistant Staphylococcus aureus colonization. Infect Control Hosp Epidemiol 32:9-19, 2011
4. Jee C, Brockstein B, Hui W, et al.: Incidence and management of bevacizumab associated hypertension in an outpatient oncology clinic. J Clin Oncol 27, 2009 (suppl; abstr e20677)
5. Menas P, Merkel D, Carro G, et al.: Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic. J Clin Oncol 28, 2010 (suppl; abstr e11062)
6. Harper A, Carro G, Brockstein B, et al.: Oral chemotherapy adherence and safety in an outpatient oncology setting. International Society of Oncology Pharmacy Practitioners/Hematology/Oncology Pharmacy Association Annual conference, June 18-21, 2008 (abstr TR41)
7. Carro G, Lawton J, Harper A, et al.: Evaluation of elastomeric and electronic medication pumps at an outpatient cancer center. Hematology/Oncology Pharmacy Association Annual conference Abstr., 2010
8. Shah NB, Fidler MJ, Walters KK, et al.: Association of epithelial mesenchymal transition (EMT) markers and outcome measures in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib. J Clin Oncol 28:550s, 2010 (suppl; abstr 7550)
9. Hensing TA, Fidler MJ, Wong F, et al.: The association between PTEN expression and survival in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with erlotinib. J Clin Oncol 28:550s, 2010 (suppl; abstr 7552)
10. Surati M, Robinson M, Nandi S, et al.: Generation of comprehensive thoracic oncology database-tool for translational research. J Vis Exp 22:pii, 2414, 2011
11. Lowes R: EMR success: Training is the key. Med Econ 81:TCP11-TCP4, 2004
12. Boonstra A, Broekhuis M: Barriers to the acceptance of electronic medical records by physicians from systematic review to taxonomy and interventions. BMC Health Ser Res 10:231, 2010